Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a rare but potentially life-threatening complication, frequently associated with Epstein-Barr virus (EBV), which develops after solid organ or stem cell transplantation. Immunosuppression received by transplant recipients has a significant impact on the development of PTLD by suppressing the function of T cells. The preferential proliferation of NKG2A-positive natural killer (NK) cells during primary symptomatic EBV infection known as infectious mononucleosis (IM) and their reactivity toward EBV-infected B cells point to a role of NK cell in the immune control of EBV. However, NK cell-mediated immune response to EBV in immunosuppressed transplant recipients who develop PTLD remains unclear. In this study, we longitudinally analyzed the phenotype and function of different NK cell subsets in a cohort of pediatric liver transplant patients who develop PTLD and compared them to those of children with IM. We found persistently elevated plasma EBV DNA levels in the PTLD patients indicating suboptimal anti-viral immune control. PTLD patients had markedly decreased frequency of CD56dimNKG2A+Killer Immunoglobulin-like receptor (KIR)− NK cells from the time of diagnosis through remission compared to those of IM patients. Whilst the proliferation of CD56dimNKG2A+KIR− NK cells was diminished in PTLD patients, this NK cell subset maintained its ability to potently degranulate against EBV-infected B cells. Compared to cytomegalovirus (CMV)-seropositive and -negative IM patients, PTLD patients co-infected with CMV and EBV had significantly higher levels of a CMV-associated CD56dimNKG2ChiCD57+NKG2A−KIR+ NK cell subset accumulating at the expense of NKG2A+KIR− NK cells. Taken together, our data indicate that co-infection of CMV and EBV diminishes the frequency of CD56dimNKG2A+KIR− NK cells and contributes to suboptimal control of EBV in immunosuppressed children with PTLD.
Highlights
Epstein-Barr Virus (EBV) is a herpesvirus that latently infects more than 90% of the world’s population [1]
Even 2 years postdiagnosis, 50% of post-transplant lymphoproliferative disorder (PTLD) patients had detectable EBV DNA levels in the plasma (Supplementary Figure 1). These results suggest that EBV DNA levels tend to persist at elevated levels in PTLD patients after clinical recovery
Measurement of EBV copies in peripheral blood mononuclear cells (PBMCs) has been reported to reflect the EBV-infected circulating B cell population [27], plasma EBV viral copies have been found to be better in predicting the clinical outcomes for the management of PTLD [33]
Summary
Epstein-Barr Virus (EBV) is a herpesvirus that latently infects more than 90% of the world’s population [1] It is renowned for its potent B-cell transforming capability to drive numerous benign and malignant lymphoproliferative disorders such as infectious mononucleosis (IM), post-transplant lymphoproliferative disorder (PTLD), and Burkitt lymphoma [2]. The preferential proliferation and accumulation of early-differentiated CD56dimNKG2A+KIR− NK cells in immunocompetent children with acute IM indicate that the NK cell compartment reacts to EBV [5]. This is highlighted by the fact that other viral infections are associated with the accumulation of another NK cell subset, such as the late-differentiated CD56dimNKG2ChiCD57+ NK cell subset upon human cytomegalovirus (CMV) infection [9]. The study of IM patients provides insight in the pathogenesis and immune control in primary EBV infection
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.